|
|||||
|
|
Low-dose recombinant canine interferon-γ for treatment of canine atopic dermatitis: An open randomized comparative trial of two doses |
|
| Authors: | Kuniyoshi Yasukawa Shiori Saito Takuya Kubo Yuya Shibasaki Kayo Yamaoka Hisae Hachimura Tomoko Kuyama Akiteru Amimoto Tsuyoshi Kumata Yuko Kitahara Masahiko Takenaka Hitoshi Matsumura Takehiro Uno Tomiya Uchino Kazutaka Takehara Kouji Nishida Michiyo Kadoya Masafumi Sato Kaoru Kato Kanako Matsumoto Satoshi Saito Tetsuya Shimoda |
| Institution: | Sanyo Animal Medical Center, 357-1, Koumoto, Akaiwa, Okayama 709-0821, Japan; Shibasaki Animal Hospital, 1-10-35, Ushidahon-cho, Higashi-ku, Hiroshima 732-0066, Japan; Amica Pet Clinic, 3-2-3, Onda-cho, Ube, Yamaguchi 755-0023, Japan; Maruyama Animal Hospital, 11-1-37, Miyanomori 1-jou, Chuo-ku, Sapporo, Hokkaido 064-0951, Japan; Pet Clinic Anihos, 1-14-11, Minamitokiwadai, Itabashi-ku, Tokyo 174-0072, Japan; Takenaka Animal Hospital, 3-10-3, Zao-cho, Fukuyama, Hiroshima 721-0971, Japan; Matsumura Animal Hospital, 2239-26, Kokubu-cho, Hamada, Shimane 697-0003, Japan; Uno Animal Hospital, 181-3, Yamadai, Kinsei-cho, Shikokuchuo, Ehime 799-0112, Japan; Veterinary ME Research Center Co. Ltd., 482-3, Ina, Akiruno, Tokyo 190-0142, Japan; Takehara Animal Hospital, 304-4, Asakawahigashi-jou, Nagano 381-0064, Japan; Medical Center Nishida Animal Hospital, 5-10-11, Ueda, Matsubara, Osaka 580-0016, Japan; Kadoya Animal Hospital, Fuchu 1-40-12, Fuchu, Tokyo 183-0055, Japan; Kariya Animal Hospital, 3-12-7, Kitasuna, Koto-ku, Tokyo 136-0073, Japan; Kato Animal Hospital, 2-286-12, Matsunami-cho, Tottori 680-0801, Japan; Yonago Animal Medical Center, 5-6-17, Yonehara, Yonago, Tottori 683-0804, Japan; Ishiyama-dori Animal Hospital, 1-25, S17, W10, Chuo-ku, Sapporo 064-0917, Japan |
| Abstract: | The purpose of this study was to investigate the minimum effective dose of recombinant canine interferon-γ (rCaIFN-γ) for the treatment of dogs with atopic dermatitis (AD). Thirty-four dogs with AD from 17 animal hospitals in Japan were administered half or one-fifth of the approved rCaIFN-γ dose of 10 000 units/kg, three times a week for 4 weeks, followed by once weekly for an additional 4 weeks. Pruritus, excoriation, erythema and alopecia were evaluated and scored by the investigators on weeks 2, 4, 6, 8 and 12. The efficacy rate (number of excellent cases + number of good cases/total number of cases) at week 8 in the 2000 units/kg group was 36.4% for pruritus, 36.4% for excoriation, 45.5% for erythema and 36.4% for alopecia. In contrast, in the 5000 units/kg group, the efficacy rate was 64.3% for pruritus, 57.1% for excoriation, 78.6% for erythema and 78.6% for alopecia. The efficacy rate of the 5000 units/kg group was high for all signs evaluated and comparable to that of the 10 000 units/kg group reported in a previous study. The results of this study showed that 2000 units/kg of rCaIFN-γ is less effective than 5000 units/kg to treat dogs with AD, and the efficacy of the 5000 units/kg dose is comparable to that of 10 000 units/kg at week 8. |
| Keywords: | |